Since IL-6 is a pleiotropic cytokine that plays important roles in the regulation of immune response and inflammation, IL-6 receptor monoclonal antibody treatment has been identified as a promising treatment for Castleman's disease, rheumatoid arthritis, juvenile idiopathic arthritis, and Crohn's disease [16-19]. Here, IL6 is linked to Crohn disease.